Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Details)

v3.22.1
SEGMENT INFORMATION (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
segment
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Segment Reporting Information [Line Items]      
Number of operating segments | segment 2    
Product sales, net $ 4,447 $ 4,844  
Gross profit 1,156 2,358  
Research and development expense 121 186  
Selling, general and administrative expense 2,550 5,285  
Operating loss (1,515) (3,113)  
Consumer Products Segment      
Segment Reporting Information [Line Items]      
Product sales, net 4,447 4,844  
Gross profit 1,156 2,358  
Research and development expense 117 128  
Selling, general and administrative expense 2,519 5,270  
Operating loss (1,480) (3,040)  
Specialty Pharmaceutical Segment      
Segment Reporting Information [Line Items]      
Product sales, net 0 0  
Gross profit 0 0  
Research and development expense 4 58  
Selling, general and administrative expense 31 15  
Operating loss (35) $ (73)  
Intangible assets $ 1,500   $ 1,500